Zobrazeno 1 - 10
of 3 932
pro vyhledávání: ''
Autor:
Charles L, Vogel, Melody A, Cobleigh, Debu, Tripathy, John C, Gutheil, Lyndsay N, Harris, Louis, Fehrenbacher, Dennis J, Slamon, Maureen, Murphy, William F, Novotny, Michael, Burchmore, Steven, Shak, Stanford J, Stewart, Michael, Press
Publikováno v:
Journal of Clinical Oncology. 41:1638-1645
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ran
Autor:
C. Meyer, Y. Fouché, Emmanuel Chamorey, M. Dejode, C. Bailleux, J. Haudebourg, Renaud Schiappa, Y. Delpech, Emmanuel Barranger
Publikováno v:
Clinical Breast Cancer. 22:121-126
Background Delays in initiating adjuvant chemotherapy after breast cancer surgery seems to have an impact on patients’ risk of relapse and their survival rate. The aim of this retrospective study was to identify factors delaying initiation of adjuv
Autor:
Masayuki Takeda, Tomohide Tamura, Kohei Akiyoshi, Masahiro Morise, Naofumi Shinagawa, Toshiaki Saeki, Naoki Inui, Morihito Okada, Shunichi Sugawara, Kaoru Kubota, Yasutaka Watanabe, Akito Hata, Isamu Okamoto
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(2)
PURPOSE We evaluated the efficacy and safety of fosnetupitant (FosNTP) versus fosaprepitant (FosAPR) for preventing highly emetogenic chemotherapy-induced nausea and vomiting. This phase III study was the first head-to-head comparison between two dif
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
BMC Cancer
BMC Cancer
Background Oral mucositis (OM) associated with cancer treatment not only impairs patients’ quality of life but also causes treatment delays or changes. This prospective exploratory study was conducted to evaluate the efficacy of Episil® oral liqui
Autor:
Hirotaka Matsumoto, Hidekazu Suzuki, Yoko Tsukita, Daisuke Arai, Satoshi Hara, Takeshi Uenami, Motohiro Tamiya, Shinsuke Tsumura, Asuka Okada, Yoshihiko Sakata, Takashi Yokoi, Hideki Ikeda, Megumi Inaba, Yuki Sato, Shinya Sakata, Hirotaka Maruyama, Hiroshi Kobe, Go Saito, Takuro Sakagami, Jun Morinaga, Ryota Shibaki, Yuko Oya
Publikováno v:
European Journal of Cancer. 159:144-153
Osimertinib is the standard of care in the initial treatment for advanced epidermal growth factor receptor (EGFR) mutation-positive lung cancer. However, clinical data and reliable prognostic biomarkers are insufficient.We performed a retrospective m
Autor:
Griselda Martrat, Jorge García-González, Guillermo Lopez-Vivanco, Santiago Viteri, J. Garde, Manuel Cobo, Miguel Sampayo, Rafael Rosell, Jose Miguel Sanchez, Niki Karachaliou, Ivanna Sullivan, Miguel Angel Molina-Vila, Andrea Malfettone, Margarita Majem
Publikováno v:
European Journal of Cancer. 159:174-181
Aim of the study The AZENT ( NCT02841579 ) study aimed to assess the efficacy and safety of first-line osimertinib in patients with epidermal growth factor receptor(EGFR)mutation–positive advanced non–small-cell lung cancer (NSCLC) and with a coe
Autor:
Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Yuki Sato, Hiroki Irie, Yoshinori Okubo, Jun Nakamura, Mika Takasumi, Minami Hashimoto, Tsunetaka Kato, Ryoichiro Kobashi, Takuto Hikichi, Hiromasa Ohira
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer
BMC Cancer
Background The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemother
Autor:
Jinyi Wang, Guohan Chen, Guangxue Wang, Xuan Hong, Zhiyuan Huang, Tian Zhao, Yejun Cao, Qiying Zhang, Zhengjun Chai, Jie Liu, Qinchuan Li, Yang Han, Zhengliang Sun
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 11, Iss 2, Pp 348-357 (2022)
Cancer Medicine, Vol 11, Iss 2, Pp 348-357 (2022)
Objective The aim of this study was to assess the efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy (IPHC) in treating malignant pleural effusion (MPE) compared to normothermic chemoperfusion of the pleural cavity (NCPC), a
Autor:
Masahiko Mori, Takayuki Nagasawa, Takayuki Enomoto, Toru Sugiyama, Yuki Inokuchi, Satoru Nagase, Shoji Kamiura, Tetsuro Oishi, Shinichi Komiyama, Tadahiro Shoji, Masakazu Abe, Nobuhiro Takeshima, Aikou Okamoto
Publikováno v:
Cancer Science
We investigated the efficacy and safety of further bevacizumab therapy in patients with platinum‐resistant ovarian cancer whose disease had progressed after bevacizumab plus chemotherapy. In this multicenter, open‐label, phase II trial (JGOG3023)
Autor:
Marie C Semira, Francis Parnis, Angelyn Anton, Peter Gibbs, Arun Azad, Javier Torres, Lavinia Spain, Ashray Gunjur, Andrew Weickhardt, Phillip Parente, Jeffrey C. Goh, Edmond M. Kwan, Shirley Wong, Ben Tran, Carmel Pezaro, J. Shapiro
Publikováno v:
European Journal of Cancer. 157:485-492
INTRODUCTION: Bone metastases occur frequently in castration-resistant prostate cancer (CRPC) and may lead to skeletal-related events (SREs), including symptomatic skeletal events (SSEs). Bone-modifying agents (BMAs) delay SREs and SSEs. However, the